BioCentury
ARTICLE | Clinical News

Human neural stem cells: Phase II discontinued

July 11, 2016 7:00 AM UTC

StemCells will wind down operations after a DMC concluded that data from the single-blind Phase II Pathway Study of HuCNS-SC cells failed the futility criteria established for the interim analysis and recommended to terminate the study. StemCells said the “magnitude of the effect and the perceived trend of the effect over time did not justify continuing the study or exploring the variability in the initial patient observations, given the financial resources available” to the company. StemCells previously reported interim data from 6 patients showing that HuCNS-SC led to improvements in both strength and function as measured by the ISNCSCI and GRASSP in 4 patients at 6 months of follow-up (see BioCentury, Nov. 23, 2015). ...